The partnership will further the system’s research and development of cell-targeted nucleic acid and gene editing therapies which Pfizer may apply to its investigational programs, according to a Feb. 12 system news release. It will also bring together UT Southwestern’s advances in RNA-based biology and therapies with Pfizer’s rapid manufacturing capabilities.
UT Southwestern’s lab has been working on RNA-based delivery systems for more than a decade.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
